Ameluz: When Danger Lurks Below the Surface (Biofrontera and Elevate Healthcare)
Approximately 8% to 10% of actinic keratosis (AK) will develop into invasive squamous cell carcinoma. When it comes to treating AK, research shows that dermatologists are very consistent and satisfied with current treatments—from cryotherapy to topicals to the most used photodynamic therapy (PDT) brand. Their satisfaction extends beyond clinical expectations. HCPs are also content with financial availability and the fit with practice and patient flow.
It was obvious that Biofrontera needed to make a big statement in order to educate physicians about a unique treatment option in this market. To do so, they enlisted the help of Elevate Healthcare.
The team designed a campaign that would change dermatologists’ behavior. It demonstrated a sense of urgency about the need to address visible and subclinical AK lesions sooner by leveraging the strong clinical data and nanoemulsion technology of Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% (and BF-RhodoLED).
An updated website features close-up photos of AK lesions that are circled by sharks just beneath the surface of the skin. The bold headline, “Danger Lurks Below the Surface,” reminds dermatologists of the threat AK lesions pose and the need for a more focused, deliberate approach to treatment.
